目的 系统评价贝伐单抗联合洛莫司汀治疗复发性胶质瘤的临床疗效与安全性。方法 全面检索中英文数据库,检索随机对照试验中探讨复发性胶质瘤患者使用贝伐单抗与洛莫司汀联合治疗的临床研究,检索时间均从建库至2023-04。2名研究者分别独立检索数据库,筛查文献后对数据进行提取、分析,并分析纳入文献的偏倚风险,采用RevMan 5.4软件进行Meta分析。结果 纳入6项随机对照试验, 共有患者1053例(试验组523例,对照组530例)。Meta分析结果显示,贝伐单抗联合洛莫司汀治疗可显著改善复发性胶质母细胞瘤患者的无进展生存期(PFS)(HR=0.52,95% CI:0.44～0.61,P<0.05)与客观缓解率(ORR)(OR=0.33,95% CI:0.14～0.78,P<0.05),对总生存期(OS)无明显改善作用(HR=0.89,95% CI:0.75～1.07,P<0.05)。不良反应方面,贝伐单抗联合洛莫司汀治疗组的蛋白尿及三级以上不良反应发生率显著高于对照组,差异有统计学意义(P<0.05),其他不良反应与对照组比较,差异无统计学意义。结论 贝伐单抗联合洛莫司汀治疗复发性胶质瘤可显著改善PFS、ORR,可优先推荐用于治疗复发性胶质母细胞瘤。同时,贝伐单抗与洛莫司汀联合治疗也与蛋白尿及三级以上不良反应率增加相关,因此在将贝伐单抗加入洛莫司汀方案之前,安全性仍需考虑。
Abstract
Objective To systematically evaluate the clinical efficacy and safety of bevacizumab combined with lomustine in the treatment of recurrent glioma.Methods A comprehensive computer search was conducted in both Chinese and English databases to search randomized controlled trials on the use of bevacizumab in combination with lomustine in patients with recurrent glioma. The search time was from the establishment of the database to April 2023. Two researchers independently searched the database, screened the literature, extracted and analyzed the data, analyzed the risk of bias in the included literature, and performed a meta-analysis using software (RevMan 5.4).Results Six randomized controlled trials were included, with a total of 1053 patients (523 in experimental group and 530 in control group). The results of Meta analysis showed that bevacizumab combined with lomustine significantly improved progression-free survival (PFS)(HR=0.52,95%CI:0.44-0.61,P<0.05)and Objective response rate (ORR)(OR=0.33,95%CI:0.14-0.78, P<0.05)in patients with recurrent glioblastoma, and had no significant on overall survival (OS)(HR=0.89,95%CI:0.75-1.07, P<0.05). In terms of adverse reactions: the incidence of proteinuria and grade Ⅲ or above adverse reactions in bevasizumab combined with lomustine was significantly higher than that in the control group, with statistical significance (P<0.05), while there was no statistical significance in other adverse reactions compared with the control group.Conclusions Bevacizumab combined with Lomustine can significantly improve PFS and ORR in patients with recurrent GBM, indicating that the combination therapy is recommended for the treatment of recurrent glioblastoma. At the same time, the combination of bevacizumab and lomustine is also associated with an increased rate of proteinuria and grade III or higher adverse reactions, so safety needs to be considered before adding bevacizumab to the lomustine regimen.
关键词
复发性胶质母细胞瘤 /
贝伐单抗 /
洛莫司汀
Key words
recurrent glioblastoma /
bevacizumab /
lomustine
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Schaff L R,Mellinghoff I K.Glioblastoma and other primary brain malignancies in adults: a review[J].JAMA, 2023, 329(7): 574-587.
[2] Luo C,Song K,Wu S,et al. The prognosis of glioblastoma: a large, multifactorial study[J]. Br J Neurosurg,2021, 35(5): 555-561.
[3] Lombardi G,De Salvo G L,Brandes A A,et al.Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial[J].Lancet Oncol,2019, 20(1):110-119.
[4] Reardon D A,Brandes A A,Omuro A,et al.Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial[J].JAMA Oncol, 2020, 6(7): 1003-1010.
[5] Lan X Y,Li D,Li S,et al.Impact of angiogenic inhibition in the treatment of newly diagnosed and recurrent glioblastoma: a meta-analysis based on randomized controlled trials[J].Eur Rev Med Pharmacol Sci,2022,26(10): 3522-3533.
[6] Ellingson B M, Wen P Y, Chang S M,et al. Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival[J].Neuro Oncol,2023,25(6):1017-1028.
[7] Taal W,Oosterkamp H M,Walenkamp A M,et al.Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial[J].Lancet Oncol, 2014, 15(9): 943-953.
[8] Heiland D H,Masalha W,Franco P,et al.Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine[J].J Neurooncol,2016, 126(3): 567-575.
[9] Weathers S P,Han X,Liu D D,et al.A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma[J].J Neurooncol,2016,129(3): 487-494.
[10] Wick W,Gorlia T,Bendszus M,et al.Lomustine and bevacizumab in progressive glioblastoma[J].N Engl J Med,2017,377(20):1954-1963.
[11] Jakobsen J N,Urup T,Grunnet K,et al.Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients[J].J Neurooncol,2018,137(2):439-446.
[12] Brandes A A,Gil-Gil M,Saran F,et al.A randomized phase ii trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma[J].Oncologist, 2019,24(4):521-528.
[13] Hundsberger T,Reardon D A,Wen P Y.Angiogenesis inhibitors in tackling recurrent glioblastoma[J].Expert Rev Anticancer Ther,2017,17(6):507-515.
[14] Beige A,Ghiringhelli F,Lecuelle J,et al.Efficacy of chemotherapy plus bevacizumab in recurrent glioblastoma multiform: a real-life study[J].Anticancer Res,2022,42(12): 5847-5858.
[15] 胡奕奕,王宏勤,段虎斌,等.贝伐单抗联合治疗方案在胶质母细胞瘤Ⅱ期/Ⅲ期临床试验的研究进展[J].中西医结合心脑血管病杂志,2021,19(12):2029-2034.
[16] Weller M,Rhun E.How did lomustine become standard of care in recurrent glioblastoma?[J].Cancer Treat Rev,2020,87(11):102029.
[17] Yoon N,Kim H S,Lee J W,et al.Targeted genomic sequencing reveals different evolutionary patterns between locally and distally recurrent glioblastomas[J].Cancer Genom Proteom,2020,17(6): 803-812.
[18] Erdem E L,Bent M J,Hoogstrate Y,et al.Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy:a report from the BELOB trial[J].Cancer Res,2016, 76(3):525-534.
[19] Herrlinger U,Tzaridis T,Mack F,et al.Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised,open-label, phase 3 trial[J].Lancet,2019,393(10172): 678-688.
[20] Lin P,Jiang H,Zhao Y J,et al.Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy[J].Int Immunopharmacol, 2021,97(9):107826.
[21] Jiguet J C,Boissonneau S,Denicolai E,et al.Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVA glio ancillary study[J].Acta Neuropathol Commun,2022,10(1): 1-10.
[22] Gittleman H,Lim D,Kattan M W,et al.An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma:NRG oncology RTOG 0525 and 0825[J].Neuro Oncol,2017,19(5): 669-677.
[23] Wang F,Cathcart S J,DiMaio D J,et al.Comparison of tumor immune environment between newly diagnosed and recurrent glioblastoma including matched patients[J].J Neurooncol,2022,159(1):163-175.
[24] Tsien C I,Pugh S L,Dicker A P,et al.NRG oncology/RTOG1205:a randomized phase ii trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma[J].J Clin Oncol, 2023,41(6):1285-1295.
[25] Kumar G,Dsouza H,Menon N,et al.Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma[J].E Cancer Med Sci, 2021,15(5):1166.
[26] Patil V M,Menon N,Chatterjee A,et al.Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: a randomised open-label phase II trial[J].E Clin Med,2022, 49:101449.
基金
福建省卫生健康中青年骨干人才培养项目(2021GGB022);福建省自然科学基金资助项目(2020J011273)
PDF(4172 KB)
